Structure Therapeutics Inc.
GPCR · XNASCIK 1888886fmd_0SVPNZENEBN6KG79T2A2G11RCXManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2022 to Sep 30, 2026, 19 periods
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Research and development | 36 | 70 | 109 | 225 |
| Total operating expenses | 53 | 103 | 158 | 177 |
| Operating income | (53) | (103) | (158) | (177) |
| Income before taxes | (51) | (89) | (122) | (141) |
| Income tax expense | 0 | 0 | 0 | 1 |
| Net income from continuing operations | (51) | (90) | (123) | (141) |
| Net income | (51) | (90) | (123) | (141) |
| Net income to common shareholders | (53) | (90) | – | – |